ACZ885

Phase 3Small molecule

Novartis

ACZ885 is one of 299 small molecule programs targeting Polymyalgia Rheumatica. It is currently in Phase 3.

Indications

Total Trials

Active Trials

298

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polymyalgia RheumaticaActive, not recruiting

Muckle-Wells SyndromeActive, not recruiting

Systemic Juvenile Idiopathic ArthritisActive, not recruiting

Abdominal Aortic AneurysmActive, not recruiting

AtherosclerosisActive, not recruiting

Metastatic MelanomaActive, not recruiting

Pulmonary SarcoidosisActive, not recruiting

AnemiaActive, not recruiting

Cryopyrin-Associated Periodic SyndromeActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Polymyalgia RheumaticaPhase 2

Active, not recruiting

Muckle-Wells SyndromePhase 3

Active, not recruiting

Systemic Juvenile Idiopathic ArthritisPhase 3

Active, not recruiting

Abdominal Aortic AneurysmPhase 2

Active, not recruiting

AtherosclerosisPhase 2

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Pulmonary SarcoidosisPhase 2

Active, not recruiting

AnemiaPhase 2

Active, not recruiting

Cryopyrin-Associated Periodic SyndromePhase 3

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

ACZ885

Novartis

Phase 3

3 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Cimzia

UCB

Preclinical

30 4

Simponi

Johnson & Johnson

Preclinical

19 5

Enbrel

IImmunex

Preclinical

64 6

Remicade

OOrganon and Co

Preclinical

43 7

Arcoxia

Novartis

Preclinical

4 8

Ilaris

Novartis

Preclinical

3 9

Celexa

AbbVie

Preclinical

1 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate

Completed· Novartis logo

Novartis·Phase 1/2·NCT00619905·53 enrolled

Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Terminated· Novartis logo

Novartis·Phase 1/2·NCT00505089·11 enrolled

Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Completed· Novartis logo

Novartis·Phase 2·NCT00504595·80 enrolled

Systemic Juvenile Idiopathic Arthritis2 trials

Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Completed· Novartis logo

Novartis·Phase 1/2·NCT00426218·26 enrolled

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Withdrawn· Novartis logo

Novartis·Phase 3·NCT01676948

Efficacy and Safety2 trials

Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).

Completed· Novartis logo

Novartis·Phase 2·NCT01242813·20 enrolled

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

Completed· Novartis logo

Novartis·Phase 3·NCT02296424·182 enrolled

Cryopyrin-Associated Periodic Syndrome2 trials

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Completed· Novartis logo

Novartis·Phase 3·NCT01302860·17 enrolled

Completed· Novartis logo

Novartis·Phase 3·NCT01576367·17 enrolled

Tics1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT00421226·48 enrolled

12 more indications

Muckle-Wells syndrome1 trial

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

Completed· Novartis logo

Novartis·Phase 3·NCT00465985·35 enrolled

Polymyalgia Rheumatica1 trial

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Terminated· Novartis logo

Novartis·Phase 2·NCT01364389·16 enrolled

Chronic Kidney Disease1 trial

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Withdrawn· Novartis logo

Novartis·Phase 3·NCT01593527

Abdominal Aortic Aneurysm1 trial

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

Terminated· Novartis logo

Novartis·Phase 2·NCT02007252·65 enrolled

Type 1 Diabetes Mellitus1 trial

ACZ885 in Type 1 Diabetes Mellitus

Withdrawn· Novartis logo

Novartis·Phase 2·NCT01322321

Wet Age-Related Macular Degeneration1 trial

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Completed· Novartis logo

Novartis·Phase 1·NCT00503022·20 enrolled

Anemia1 trial

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Completed· Novartis logo

Novartis·Phase 2·NCT02961218·49 enrolled

Prevention1 trial

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Completed· Novartis logo

Novartis·Phase 3·NCT01470989·136 enrolled

Atherosclerosis1 trial

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Completed· Novartis logo

Novartis·Phase 2·NCT00995930·189 enrolled

Pulmonary Sarcoidosis1 trial

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Completed· Novartis logo

Novartis·Phase 2·NCT02888080·40 enrolled

Metastatic Melanoma1 trial

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Completed· Novartis logo

Novartis·Phase 2·NCT03484923·196 enrolled

Unspecified1 trial

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Completed· Novartis logo

Novartis·Phase 1·NCT02900664·283 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for ACZ885. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACZ885 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACZ885. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

ACZ885

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Systemic Juvenile Idiopathic Arthritis2 trials

Efficacy and Safety2 trials

Cryopyrin-Associated Periodic Syndrome2 trials

Tics1 trial

Muckle-Wells syndrome1 trial

Polymyalgia Rheumatica1 trial

Chronic Kidney Disease1 trial

Abdominal Aortic Aneurysm1 trial

Type 1 Diabetes Mellitus1 trial

Wet Age-Related Macular Degeneration1 trial

Anemia1 trial

Prevention1 trial

Atherosclerosis1 trial

Pulmonary Sarcoidosis1 trial

Metastatic Melanoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News